For instance, by integrated doxycycline dose-dependent oncofusion gene expression, e.g., KMT2A-MLLT3 (MLL-AF9) or RUNX1-RUNX1T1 (AML1-ETO), AML programs can be identified in the context of in vitro iPSC-derived hematopoietic differentiation (Tijchon et al., 2019; Heuts et al., 2023). This evidence concerns the gene RUNX1T1 and acute myeloid leukemia.